688075 安旭生物
已收盘 04-22 15:00:01
资讯
新帖
简况
安旭生物收盘上涨1.20%,滚动市盈率23.54倍,总市值47.34亿元
金融界 · 58分钟前
安旭生物收盘上涨1.20%,滚动市盈率23.54倍,总市值47.34亿元
安旭生物获得外观设计专利授权:“凝血检验盘片”
证券之星 · 03-10
安旭生物获得外观设计专利授权:“凝血检验盘片”
安旭生物03月05日获主力加仓45万元
市场透视 · 03-05
安旭生物03月05日获主力加仓45万元
安旭生物涨5.26%创近3月新高
智选洞察 · 03-05
安旭生物涨5.26%创近3月新高
安旭生物03月04日主力净流入20万元 散户资金抛售
市场透视 · 03-04
安旭生物03月04日主力净流入20万元 散户资金抛售
中国脑机接口行业发展与展望:医疗器械专题之脑机接口
华安证券股份有... · 03-03
中国脑机接口行业发展与展望:医疗器械专题之脑机接口
安旭生物02月28日遭主力抛售6万元
市场透视 · 02-28
安旭生物02月28日遭主力抛售6万元
公司深度报告:“产品+营销”双轮驱动,塑造家用医疗器械领先品牌
信达证券 · 02-28
公司深度报告:“产品+营销”双轮驱动,塑造家用医疗器械领先品牌
安旭生物(688075.SH):2024年度净利润2.01亿元 同比增长42.06%
智通财经 · 02-27
安旭生物(688075.SH):2024年度净利润2.01亿元 同比增长42.06%
安旭生物:请参考公司公开信息
证券之星 · 02-19
安旭生物:请参考公司公开信息
医药生物行业周报:影像云索引打通医疗数据共享
世纪证券有限责... · 02-16
医药生物行业周报:影像云索引打通医疗数据共享
医疗耗材行业周报:持续关注医疗器械国产替代与创新迭代
湘财证券股份有... · 02-12
医疗耗材行业周报:持续关注医疗器械国产替代与创新迭代
医药行业周报:诺华三抗新药PIT565在华再获批临床 用于SLE
太平洋证券股份... · 02-10
医药行业周报:诺华三抗新药PIT565在华再获批临床 用于SLE
2月5日安旭生物(688075)龙虎榜数据
证券之星 · 02-05
2月5日安旭生物(688075)龙虎榜数据
医药生物周报:海外制药及医疗器械企业JPM 大会业务进展更新
国信证券 · 01-21
医药生物周报:海外制药及医疗器械企业JPM 大会业务进展更新
突发重磅消息:欧盟评估限制中国医疗器械供应商参与政府招标
医疗器械创新网 · 01-17
突发重磅消息:欧盟评估限制中国医疗器械供应商参与政府招标
医疗器械行业深度分析:医疗器械产业链分析及河南产业概况
中原证券 · 01-16
医疗器械行业深度分析:医疗器械产业链分析及河南产业概况
公司概况
公司名称:
杭州安旭生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2021-11-18
主营业务:
杭州安旭生物科技股份有限公司专注于POCT试剂及仪器的研发、生产与销售。公司主要产品为POCT试剂及仪器。公司拥有抗原抗体自主研发生产的生物原料技术平台,以及成熟的免疫层析及干式生化诊断技术平台,发展形成了覆盖毒品检测、传染病检测、慢性病检测、妊娠检测、肿瘤检测、心肌检测、生化检测、过敏原检测八大领域的POCT试剂,产品远销美国、德国、英国、加拿大、俄罗斯、墨西哥、泰国、印尼及波兰等150多个国家,已成为国内少数几家在POCT国际市场能够与跨国体外诊断行业巨头竞争的中国体外诊断产品供应商之一。
发行价格:
78.28
{"stockData":{"symbol":"688075","market":"SH","secType":"STK","nameCN":"安旭生物","latestPrice":37.25,"timestamp":1745305201000,"preClose":36.81,"halted":0,"volume":377076,"delay":0,"changeRate":0.012,"floatShares":127000000,"shares":127000000,"eps":0.7122,"marketStatus":"已收盘","change":0.44,"latestTime":"04-22 15:00:01","open":36.57,"high":37.35,"low":36.57,"amount":13995800,"amplitude":0.0212,"askPrice":37.34,"askSize":2,"bidPrice":37.25,"bidSize":26,"shortable":0,"etf":0,"ttmEps":0.7122,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745371800000},"marketStatusCode":5,"adr":0,"adjPreClose":36.81,"symbolType":"stock_kcb","openAndCloseTimeList":[[1745285400000,1745292600000],[1745298000000,1745305200000]],"highLimit":40.49,"lowLimit":33.13,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":127082805,"isCdr":false,"pbRate":0.92,"roa":"--","peRate":52.302724,"roe":"2.62%","epsLYR":1.11,"committee":-0.278195,"marketValue":4734000000,"turnoverRate":0.003,"status":0,"afterMarket":{"amount":0,"volume":0,"close":37.25,"buyVolume":0,"sellVolume":0,"time":1745307238029,"indexStatus":"已收盘 04-22 15:30:00","preClose":36.81},"floatMarketCap":4734000000},"requestUrl":"/m/hq/s/688075/wiki","defaultTab":"wiki","newsList":[{"id":"2529371506","title":"安旭生物收盘上涨1.20%,滚动市盈率23.54倍,总市值47.34亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529371506","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529371506?lang=zh_cn&edition=full","pubTime":"2025-04-22 18:53","pubTimestamp":1745319232,"startTime":"0","endTime":"0","summary":"4月22日,安旭生物今日收盘37.25元,上涨1.20%,滚动市盈率PE达到23.54倍,创13天以来新低,总市值47.34亿元。从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均48.08倍,行业中值30.21倍,安旭生物排名第56位。截至2024年三季报,共有1家机构持仓安旭生物,其中基金1家,合计持股数16.47万股,持股市值0.07亿元。最新一期业绩显示,2024年三季报,公司实现营业收入4.03亿元,同比27.56%;净利润1.36亿元,同比-27.33%,销售毛利率42.11%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/22185349761015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2518202438","title":"安旭生物获得外观设计专利授权:“凝血检验盘片”","url":"https://stock-news.laohu8.com/highlight/detail?id=2518202438","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518202438?lang=zh_cn&edition=full","pubTime":"2025-03-11 03:14","pubTimestamp":1741634076,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示安旭生物新获得一项外观设计专利授权,专利名为“凝血检验盘片”,专利申请号为CN202430353581.1,授权日为2025年3月11日。今年以来安旭生物新获得专利授权4个,较去年同期减少了42.86%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100003347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688075","BK0239"],"gpt_icon":0},{"id":"2517676709","title":"安旭生物03月05日获主力加仓45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517676709","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517676709?lang=zh_cn&edition=full","pubTime":"2025-03-05 15:21","pubTimestamp":1741159268,"startTime":"0","endTime":"0","summary":"03月05日, 安旭生物股价涨3.12%,报收41.34元,成交金额8487万元,换手率1.62%,振幅6.34%,量比1.99。安旭生物今日主力资金净流入45万元,上一交易日主力净流入20万元。|03月05日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|元道通信|9.05%|#|卓翼科技|7.54%|#|祥明智能|5.65%|#|山东矿机|5.17%|#|本川智能|4.90%|#|新力金融|4.81%|#|三维通信|4.55%|#|翔腾新材|4.12%|#|宜安科技|4.11%|#|武汉凡谷|3.91%|安旭生物所在的医疗器械行业,今日主力净流出3.86亿元,行业排名25/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305161718abe9305e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305161718abe9305e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2517953543","title":"安旭生物涨5.26%创近3月新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2517953543","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517953543?lang=zh_cn&edition=full","pubTime":"2025-03-05 11:01","pubTimestamp":1741143682,"startTime":"0","endTime":"0","summary":"03月05日,安旭生物股价大幅上涨,截至11点01分,安旭生物上涨5.26%,报42.20元/股,创近3个月新高,成交4661万元,换手率0.90%,振幅5.86%。资金动向截止发稿,安旭生物获得主力净流入285万元,其中超大单流入13万元,大单流入272万元。主营业务及业绩安旭生物公司主营业务为POCT试剂及仪器的研发、生产与销售。最新财报显示,今年三季报,安旭生物实现营业收入4.03亿元,同比增长27.56%,净利润为1.36亿元,同比减少27.33%,基本每股收益为1.07元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305110127989c7aa1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305110127989c7aa1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2516564440","title":"安旭生物03月04日主力净流入20万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2516564440","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516564440?lang=zh_cn&edition=full","pubTime":"2025-03-04 15:20","pubTimestamp":1741072832,"startTime":"0","endTime":"0","summary":"03月04日, 安旭生物股价涨0.63%,报收40.09元,成交金额3295万元,换手率0.65%,振幅2.69%,量比0.87。安旭生物今日主力资金净流入20万元,上一交易日主力净流出79万元。该股近5个交易日上涨7.60%,主力资金累计净流出583万元;近20日主力资金累计净流出701万元,其中净流出天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304161202a25e8217&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304161202a25e8217&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688075","BK0239"],"gpt_icon":0},{"id":"2516942276","title":"中国脑机接口行业发展与展望:医疗器械专题之脑机接口","url":"https://stock-news.laohu8.com/highlight/detail?id=2516942276","media":"华安证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516942276?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:00","pubTimestamp":1741017600,"startTime":"0","endTime":"0","summary":"政策引导+技术突破,全球脑机接口产业进入高速发展阶段,中国非侵入式脑机接口技术全球领先。中国围绕非侵入式脑机接口方向,实现弯道超车,首创实现“双环路”脑机交互系统,打破了传统脑机接口的信息交互,并极大突破了操控时间的限制,该技术突破使得中国在非侵入式脑机接口领域处于全球领先地位。医疗健康是当前脑机接口最成熟的赛道,覆盖神经疾病诊断、康复治疗及功能替代。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304094553989abda6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304094553989abda6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688767","688108","603205","688085","688212","688151","600807","688575","BK0146","688338","600529","603987","688426","BK0251","603222","688198","688677","603880","688271","603309","BK0070","688399","688253","688606","688013","600055","688067","688351","688393","688193","688301","688314","688607","688366","688580","688075","603387","688273","688217","688358","603301","603976","688016","BK0114","600645","688289","688410","688576","688626","688161","688068","688277","159883","688298","688236","688050","688581","600587","688029","688468","688317","688617","605369","688026","688114","688139","688613","688389","603658","688656"],"gpt_icon":0},{"id":"2514108613","title":"安旭生物02月28日遭主力抛售6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514108613","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514108613?lang=zh_cn&edition=full","pubTime":"2025-02-28 15:22","pubTimestamp":1740727330,"startTime":"0","endTime":"0","summary":"02月28日, 安旭生物股价跌1.51%,报收38.60元,成交金额3090万元,换手率0.62%,振幅4.03%,量比1.04。安旭生物今日主力资金净流出6万元,连续5日净流出,上一交易日主力净流出48万元。该股近5个交易日上涨0.60%,主力资金累计净流出695万元;近20日主力资金累计净流出666万元,其中净流出天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228164638abe08573&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228164638abe08573&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2514357908","title":"公司深度报告:“产品+营销”双轮驱动,塑造家用医疗器械领先品牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2514357908","media":"信达证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514357908?lang=zh_cn&edition=full","pubTime":"2025-02-28 08:06","pubTimestamp":1740701178,"startTime":"0","endTime":"0","summary":"鱼跃医疗本期内容提要:核心观点:我们认为在人口老龄化的背景下,居民健康管理及家庭康养需求提升,家用医疗器械产品市场规模有望逐步扩大。公司作为国内领先的家用医疗器械厂商,随着产品管线逐步丰富,品牌影响力不断增强,市场份额有望不断提升,业务有望保持稳健增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022808062298957ecb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022808062298957ecb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688317","600055","688217","688613","688050","603309","688626","603976","603205","600807","BK0251","603387","688576","688253","688067","688358","688277","688389","688767","603658","688399","688410","BK0146","BK0114","688068","688581","688677","688198","688114","600587","688236","688273","688607","688029","688393","688271","688468","600645","688108","688575","603301","688426","688606","688289","688617","688314","688013","688366","603222","688193","603987","600529","688298","BK0070","688151","688075","688212","688301","688338","688656","159883","688139","688161","688085","603880","688580","688351","605369"],"gpt_icon":0},{"id":"2514879501","title":"安旭生物(688075.SH):2024年度净利润2.01亿元 同比增长42.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514879501","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514879501?lang=zh_cn&edition=full","pubTime":"2025-02-27 17:59","pubTimestamp":1740650354,"startTime":"0","endTime":"0","summary":"智通财经APP讯,安旭生物(688075.SH)发布2024年度业绩快报,报告期内公司实现营业收入5.55亿元,同比增长10.29%;归属于母公司所有者的净利润2.01亿元,同比增长42.06%;归属于母公司所有者的扣除非经常性损益的净利润3539.52万元,同比减少32.38%;基本每股收益1.58元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688075"],"gpt_icon":0},{"id":"2512177851","title":"安旭生物:请参考公司公开信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2512177851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512177851?lang=zh_cn&edition=full","pubTime":"2025-02-19 18:30","pubTimestamp":1739961036,"startTime":"0","endTime":"0","summary":"证券之星消息,安旭生物(688075)02月19日在投资者关系平台上答复投资者关心的问题。投资者:董秘您好!贵司或者子公司是否有打算接入DEEPSEEK或使用AI技术提高精准医疗和基因编辑等?是否有使用AI提高病理诊断效率?安旭生物董秘:尊敬的投资者,您好:请参考公司公开信息,感谢您的关注!以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021900033131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2512446913","title":"医药生物行业周报:影像云索引打通医疗数据共享","url":"https://stock-news.laohu8.com/highlight/detail?id=2512446913","media":"世纪证券有限责...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512446913?lang=zh_cn&edition=full","pubTime":"2025-02-17 00:00","pubTimestamp":1739721600,"startTime":"0","endTime":"0","summary":"2) 医保局推出医保影像云索引,打通医疗数据共享。长期以来,跨医院、地区层面的医疗数据共享困难,医保局此次推动的医保影像云索引为每位患者的影像检查文件赋予唯一标识,有效推动我国医疗机构间的影像信息共享,减少患者重复检查的负担,提升医疗服务效率,也有利于医保部门后期通过云端数据监管诊疗行为。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021710494098881691&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021710494098881691&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688468","688575","688410","688050","603309","603205","163118","688013","000808.SH","688399","688389","688301","600529","688606","688273","688581","688139","688767","688217","688075","688626","BK0070","688358","688161","688613","688366","688212","688108","603301","688617","600807","688314","688576","BK0114","688085","688114","688317","688067","603658","688029","603222","603976","688277","688580","605369","603987","688236","600645","159891","688253","688026","688271","BK0251","600055","688151","BK0146","603387","688016","688298","688351","688068","688338","688393","603880","688198","688426","688289","688656","688677","600587","688193"],"gpt_icon":0},{"id":"2511982595","title":"医疗耗材行业周报:持续关注医疗器械国产替代与创新迭代","url":"https://stock-news.laohu8.com/highlight/detail?id=2511982595","media":"湘财证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511982595?lang=zh_cn&edition=full","pubTime":"2025-02-13 00:00","pubTimestamp":1739376000,"startTime":"0","endTime":"0","summary":"医疗耗材报收5254.51 点,上涨1.69%。医疗耗材板块震荡上行。脉冲场消融系统在美国和欧洲、中东及非洲地区的良好市场接受度,以及在日本和中国的成功上市。在行业政策面支持态度明确的情况下,叠加部分上市公司业绩迎来拐点,看好医疗耗材相关企业行情上涨潜力。医疗耗材行业中随着国家与地方性集采的持续深化,国产化进程进一步推进,仍需把握国产替代与创新技术迭代的主线。维持医疗耗材行业的“增持”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021311380696211d65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021311380696211d65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688410","688139","603309","688317","688606","688426","688607","688085","603987","688067","688236","688013","600807","600587","688271","688277","688656","688580","688617","688389","688108","688393","688358","600529","688212","603222","688016","688351","688301","688217","688068","688026","688613","159891","600055","603658","688399","603205","603387","688151","688198","688114","688581","603880","688468","688161","688273","688626","688767","688253","688576","688575","688050","688298","603301","159883","600645","688338","BK0239","688029","688075","688366","603976","605369","688314","688677","688289","688193","BK0251"],"gpt_icon":0},{"id":"2510277958","title":"医药行业周报:诺华三抗新药PIT565在华再获批临床 用于SLE","url":"https://stock-news.laohu8.com/highlight/detail?id=2510277958","media":"太平洋证券股份...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510277958?lang=zh_cn&edition=full","pubTime":"2025-02-11 00:00","pubTimestamp":1739203200,"startTime":"0","endTime":"0","summary":"行业要闻:近日,中国国家药监局药品审评中心官网公示,诺华申报的1 类新药PIT565 获得一项新的临床试验默示许可,拟开发治疗系统性红斑狼疮。PIT565 是一款抗CD3/CD19/CD2 的三特异性抗体,可以靶向恶性B 细胞上的CD19,同时可与T 细胞上的CD3和CD2结合。与CD3 双特异性相比,通过PIT565共刺激CD2 可能会克服T 细胞衰竭,增加患者反应的深度和持续时间,该药此前在华获批针对B 细胞恶性肿瘤的IND。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211120756961eb981&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211120756961eb981&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688389","688016","688505","600267","688176","600645","605507","603520","601089","688553","688075","688602","600812","600055","688658","603538","688576","688013","688189","688076","603207","688613","688221","603658","688767","688050","603168","600789","688236","688607","688399","603669","688799","688626","603301","603351","688198","688580","600624","688217","600062","603367","688062","688617","688581","600513","BK0188","605369","688298","BK0060","603676","688468","BK0028","688117","600079","603987","600807","688321","688266","600521","603707","688506","603309","603387","688247","688193","688026","688356","688091","688166","688273","688428","603222","600488","688575","BK0239","600587","688513","688426","600774","688271","600276","603811","688382","688677","688197","600664","688139","688212","600420","688578","605177","603880","688235","603205","605116","688358","688566","600200","603976","600529","688302","688108","688161","600613","688317","688690","600216","688338","688373","688067","603229","688029","688151","688606","600196","688192","688758","688085","600851","600380"],"gpt_icon":0},{"id":"2509408313","title":"2月5日安旭生物(688075)龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2509408313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509408313?lang=zh_cn&edition=full","pubTime":"2025-02-05 17:52","pubTimestamp":1738749140,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2025年2月5日公布的交易公开信息显示,安旭生物因单只标的证券的当日融资买入数量达到当日该证券总交易量的50%以上登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年2月5日收盘,安旭生物报收于38.07元,上涨0.5%,换手率0.32%,成交量4031.0手,成交额1527.75万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020500027248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688075"],"gpt_icon":0},{"id":"2505480758","title":"医药生物周报:海外制药及医疗器械企业JPM 大会业务进展更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2505480758","media":"国信证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505480758?lang=zh_cn&edition=full","pubTime":"2025-01-22 00:00","pubTimestamp":1737475200,"startTime":"0","endTime":"0","summary":"本周医药板块表现弱于整体市场,生物制品板块领涨。分子板块来看,化学制药上涨2.84%,生物制品上涨3.19%,医疗服务上涨2.18%,医疗器械上涨3.08%,医药商业上涨1.72%,中药上涨2.08%。波士顿科学:预计2024 全年有机销售额约160 亿美元,调整后营业利润率27% , 调整后EPS 为2.45-2.47 美元。公司把实现30%的调整后营业利润率及持续两位数的EPS 增长作为长期经营目标。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122092134abb3d27e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122092134abb3d27e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603976","BK0273","688351","688315","600807","688622","688576","000808.SH","688075","688067","688271","688581","688151","688767","688338","688358","688273","BK0095","688607","159883","BK0188","603309","688613","BK0139","688277","BK0077","BK0239","BK0200","163118"],"gpt_icon":0},{"id":"2504187100","title":"突发重磅消息:欧盟评估限制中国医疗器械供应商参与政府招标","url":"https://stock-news.laohu8.com/highlight/detail?id=2504187100","media":"医疗器械创新网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504187100?lang=zh_cn&edition=full","pubTime":"2025-01-17 16:01","pubTimestamp":1737100880,"startTime":"0","endTime":"0","summary":"在2024年4月24日,欧盟首次动用IPI对中国医疗采购进行调查,旨在消除对中国政府偏袒本土供应商的担忧,确保其公共采购市场的公平与开放。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117160815a2254f22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117160815a2254f22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603309","688075","688613","688617","688338","688581","688767","603880","603122","159883","688607","688677","BK0250","688151","688277","688351","603976"],"gpt_icon":0},{"id":"2504132081","title":"医疗器械行业深度分析:医疗器械产业链分析及河南产业概况","url":"https://stock-news.laohu8.com/highlight/detail?id=2504132081","media":"中原证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504132081?lang=zh_cn&edition=full","pubTime":"2025-01-17 00:00","pubTimestamp":1737043200,"startTime":"0","endTime":"0","summary":"河南医疗器械产业发展情况。河南省医疗器械及卫材产业2022 年产业规模超过450 亿元,相较于2018 年实现翻番,年均增长率超过15%,在全国处于中上游水平,生产企业数量居全国第6位,并且仍在保持高速增长。目前河南地区医疗器械产业发展仍存在集群化程度低、企业规模普遍偏小,产业链结构偏低端局限。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117182238abae6b1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117182238abae6b1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688075","688617","BK0146","688013","BK0251","603880","605369","688277","BK0070","688338","688613","688273","159883","BK0114","600055","603122","603976","688607","688677","603309","688212","688085","688600","688767","688351","688581","688358","688468","688151","688067"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1745322694349,"stockEarnings":[{"period":"1week","weight":-0.0062},{"period":"1month","weight":-0.0827},{"period":"3month","weight":-0.0282},{"period":"6month","weight":-0.0293},{"period":"1year","weight":0.152},{"period":"ytd","weight":-0.0019}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":-0.0218},{"period":"3month","weight":0.0151},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.0738},{"period":"ytd","weight":-0.018}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州安旭生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6697人(较上一季度减少2.22%)","perCapita":"18976股","listingDate":"2021-11-18","address":"浙江省杭州市余杭区莫干山路1418-50号4幢3层(上城科技工业基地)","registeredCapital":"12708万元","survey":" 杭州安旭生物科技股份有限公司专注于POCT试剂及仪器的研发、生产与销售。公司主要产品为POCT试剂及仪器。公司拥有抗原抗体自主研发生产的生物原料技术平台,以及成熟的免疫层析及干式生化诊断技术平台,发展形成了覆盖毒品检测、传染病检测、慢性病检测、妊娠检测、肿瘤检测、心肌检测、生化检测、过敏原检测八大领域的POCT试剂,产品远销美国、德国、英国、加拿大、俄罗斯、墨西哥、泰国、印尼及波兰等150多个国家,已成为国内少数几家在POCT国际市场能够与跨国体外诊断行业巨头竞争的中国体外诊断产品供应商之一。","listedPrice":78.28},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安旭生物(688075)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安旭生物(688075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安旭生物,688075,安旭生物股票,安旭生物股票老虎,安旭生物股票老虎国际,安旭生物行情,安旭生物股票行情,安旭生物股价,安旭生物股市,安旭生物股票价格,安旭生物股票交易,安旭生物股票购买,安旭生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安旭生物(688075)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安旭生物(688075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}